<DOC>
	<DOCNO>NCT00307580</DOCNO>
	<brief_summary>This Phase IV , open-label , single-arm , multicenter trial conduct ~60 site United States . Approximately 300 pediatric subject dysfunctional CVADs ( include catheter valve , multiple lumen , umbilical catheter , implanted port ) treat two serially instilled dos Cathflo Activase .</brief_summary>
	<brief_title>Cathflo Activase Pediatric Study</brief_title>
	<detailed_description />
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Subjects meet follow inclusion criterion eligible study entry : Less 17 year age Clinically stable Occlusion CVAD ( include catheter valve , multiple lumen , umbilical catheter , implanted port ) For subject weigh &gt; = 10 kg , inability withdraw 3 mL blood CVAD For subject weigh &lt; 10 kg , inability withdraw 1 mL blood CVAD Ability infuse fluid volume necessary instill Cathflo Activase CVAD Written inform consent assent ( appropriate ) provide parent legal guardian compliance study assessment full duration study Ability withdraw blood follow subject reposition CVAD insertion &lt; 48 hour prior enrollment Selected study catheter implant specifically hemodialysis Evidence mechanical , nonthrombotic occlusion CVAD ( e.g. , kink CVAD suture constrict catheter ) Previous enrollment study Use fibrinolytic agent ( e.g. , alteplase , reteplase , tenecteplase , urokinase , streptokinase ) within 24 hour enrollment At high risk bleed event , embolic complication ( i.e. , recent pulmonary embolism , deep vein thrombosis , endarterectomy , clinically significant righttoleft shunt ) opinion investigator , know condition bleed constitute significant hazard Known hypersensitivity alteplase component formulation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>CVADS</keyword>
</DOC>